Puma Biotechnology, Inc.
PBYI
$6.07
$0.172.88%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 38.51% | 3.89% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 38.51% | 3.89% | |||
| Cost of Revenue | 89.99% | -1.04% | |||
| Gross Profit | 23.70% | 5.40% | |||
| SG&A Expenses | 9.29% | -6.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 29.94% | -1.96% | |||
| Operating Income | 78.69% | 44.26% | |||
| Income Before Tax | 85.08% | 49.93% | |||
| Income Tax Expenses | 819.55% | 28.71% | |||
| Earnings from Continuing Operations | 51.94% | 51.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 51.94% | 51.05% | |||
| EBIT | 78.69% | 44.26% | |||
| EBITDA | 54.23% | 30.81% | |||
| EPS Basic | 51.91% | 49.15% | |||
| Normalized Basic EPS | 85.02% | 48.13% | |||
| EPS Diluted | 51.65% | 44.31% | |||
| Normalized Diluted EPS | 82.98% | 47.66% | |||
| Average Basic Shares Outstanding | 0.00% | 1.29% | |||
| Average Diluted Shares Outstanding | 1.16% | 1.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||